Ajinomoto

Activities: Manufacturing Ingredients Packaging Research & Development Active Nutrition Food Nutraceutical

Trending Articles

  1. The new F-Gas Regulation and its impact on pharmaceutical freeze-drying Freeze-drying or lyophilization represents a pivotal process in the life sciences industry. During the past five decades, the technology involved has evolved into a complex,...
  2. Quantoom Biosciences, Univercells and Fiocruz collaborate to advance global RNA vaccine development Together, the companies will develop RNA-based biopharmaceuticals, while also building a dedicated mRNA production facility in Brazil
  3. Gerresheimer begins €100m expansion of its pharmaceutical syringe production capabilities The extension of its Skopje, North Macedonia site will allow Gerresheimer to better serve the pharmaceutical and biotech industries
  4. Ipsen licenses Biomunex Pharmaceuticals' bispecific antibody, BMX-502 The deal makes Biomunex eligible for up to $610m, with Ipsen being responsible for getting the cancer immunotherapy into Phase I clinical trials
  5. Europa Biosite acquires life science product and service supplier, AMSBIO Europa Biosite will now be able to expand its presence across the key US market, while also bolstering its offerings in stem cell research, regenerative medicine and biospecimens

Upcoming event

CPhI Middle East

10–12 December 2024 | Conference | Riyadh, Saudi Arabia See all

Related Content

Manufacturing

Ajinomoto expands small molecule manufacturing in India

CDMO Ajinomoto Bio-Pharma Services has announced plans for construction of a 8,500 sqm facility
Manufacturing

Ajinomoto Bio-Pharma Services buys out joint venture company

The purchase will transfer the remaining 50% ownership of Granules OmniChem from Ajinomoto’s joint venture partner, Granules India
Media

Seventure Partners announces sale of Cambrooke to Ajinomoto

Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in the venture investment in the microbiome sector, announced the trade sale of its portfolio company Cambrooke Therapeutics, US, to Ajinomoto
Digital

CGT Catapult licenses cell culture data to Ajinomoto

Ajinomoto made use of data from CGT Catapult’s work on pluripotent stem cell processes and development
Subscribe now